Furthermore, bone marrow aspirates collected from NSGS mice engrafted with TP53-mutated MDS/AML cells enabled randomization to treatment with either anti-CCRL2 ADC or an isotype control. This evidence concerns the gene TP53 and myelodysplastic syndrome.